
|Articles|June 15, 2003
MedPointe to sell drug for itchy, allergic eyes
Somerset, NJ-MedPointe Inc. has acquired all U.S. and Canadian rights to azelastine HCl (Optivar), a treatment for itching of the eye associated with allergic conjunctivitis in adults and children ages 3 and older.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies
3
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
4
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis
5



























